Abstract
Introduction

The incidence of malignant lymphoma has increased 60 to 200 fold in individuals who are infected with HIV (1, 2). It is included in AIDS-defining diseases, in which the diagnosis determines that the patient with positive HIV is affected with AIDS. Since the introduction of highly active anti-retroviral therapy (HAART), the risk of opportunistic infection has been reduced and the prognosis of HIV infected patients has improved; nevertheless, AIDS related lymphoma (ARL) is still a major cause of death of HIVinfected patients. Encouragingly, however, the recent reports of studies of first line chemotherapy for ARL, such as dose-adjusted EP-OCH (3), R-CHOP (4), and R-CDE (5)
,
Discussion
High-dose chemotherapy followed by autologous stem cell transplantation for high risk first remission, refractory to first-line chemotherapy or relapsed ARL has been reported by several institutes. The first study on ASCT for ARL was reported by Gabarre et al in 2000 (6). Krishnan et al reported long-term remission in 20 patients of high risk ARL (7). In terms of conditioning regimen, CBV (cyclophosphamide, BCNU, etoposide) (6), BEAM (BCNU, etoposide,
F i g u r e 1 . T r a n s i t i o n o f CD4 p o s i t i v e c e l l c o u n t b e f o r e a n d a f t e r ME AM wi t h a u t o l o g o u s s t e m c e l l t r a n s p l a n t a t i o n ( AS CT ) .
cytarabine, melphalan) (8), total body irradiation-based regimen (6), and BU-CY (busulfan, cyclophosphamide)
. The published study about the MEAM regimen followed by ASCT was small, and the efficacy of the MEAM regimen was not fully known (11) . All three cases T a b l e 3 . S u mma r y o f T h r e 
